Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Baxter
Harvard Business School
Moodys
Mallinckrodt

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Bitopertin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Bitopertin?

Bitopertin is an investigational drug.

There have been 10 clinical trials for Bitopertin. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Schizophrenia, Disease, and Compulsive Personality Disorder. The leading clinical trial sponsors are Hoffmann-La Roche, Niuvanniemi Hospital, and Karolinska Institutet.

There are thirteen US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for Bitopertin
TitleSponsorPhase
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Beta-ThalassemiaHoffmann-La RochePhase 2
A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.Hoffmann-La RochePhase 1
Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.Karolinska InstitutetPhase 2

See all Bitopertin clinical trials

Clinical Trial Summary for Bitopertin

Top disease conditions for Bitopertin
Top clinical trial sponsors for Bitopertin

See all Bitopertin clinical trials

US Patents for Bitopertin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bitopertin   Start Trial 5-HT3 receptor antagonists Takeda Pharmaceutical Company Limited (Osaka-Shi, Osaka, JP)   Start Trial
Bitopertin   Start Trial Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.- 3.1]nonan-7-yl)-1H-indole-3-carboxamide Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Bitopertin   Start Trial 5-HT3 receptor antagonists Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Bitopertin   Start Trial Benzoyl-piperazine derivatives Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
Bitopertin   Start Trial Benzoyl-piperazine derivatives Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bitopertin

Drugname Country Document Number Estimated Expiration Related US Patent
Bitopertin Argentina 091781 2032-07-17   Start Trial
Bitopertin Australia 2013290375 2032-07-17   Start Trial
Bitopertin Brazil 112015001028 2032-07-17   Start Trial
Bitopertin Canada 2879115 2032-07-17   Start Trial
Bitopertin Chile 2015000121 2032-07-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Merck
Baxter
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.